Hematology & Oncology
Showing 41-60 of 123 Results
-
Michael Jeng
Professor of Pediatrics (Hematology/Oncology)
Current Research and Scholarly InterestsResearch interests focus on: 1) histiocytic disorders, such as Langerhans cell histiocytosis (LCH) and hemophagocytic lymphohistiocytosis (HLH), and 2) vascular anomalies and malformations.
-
Claire Johns
Clinical Assistant Professor, Pediatrics - Hematology & Oncology
BioFellowship: Pediatric Hematology Oncology Fellowship, Stanford Lucile Packard Children's Hospital 2022-2025
Residency: Pediatrics, University of California San Francisco 2019-2022
Medical School: University of California San Francisco, Class of 2019 -
Aanchal Preet Kaur
Postdoctoral Scholar, Hematology-Oncology
BioDr. Aanchal Preet Kaur is a post-doctoral fellow in the Ramakrishna lab interested in understanding the role of myeloid cells in driving immunosuppression and resistance to CAR T cell therapies in pediatric patients with diffuse midline glioma. Her work involves developing organoid models to study the interaction of myeloid cells and CAR T cells and further employ these models to validate targets identified in patient single cell sequencing data using CRISPR technology.
Dr. Aanchal Preet Kaur received her PhD in Oncology at the University of Nottingham, United Kingdom where she focused on developing dendritic cell vaccines for melanoma. In her earlier post-doctoral work at Providence Cancer Institute with Dr. Michael Gough, she developed spheroid models to study the impact of radiation therapy on immune cell-cancer cell interactions. -
Yong Yean Kim
Assistant Professor of Pediatrics ( Hematology & Oncology)
BioOur lab is interested in translational science to bring new therapies to clinical trials. In particular, we are interested in pediatric sarcomas which have not had advancement in clinical treatment for decades. Current projects in the lab focus on understanding of the biology of fusion transcription factor PAX3::FOXO1 which is the driver mutation in fusion positive rhabdomyosarcoma. PAX3::FOXO1 is a powerful oncogenic transcription factor which rewires the transcriptional organization to lock the cancer cell in the proliferative state. Since transcription factors including PAX3::FOXO1 are difficult to target using small molecules, we aim to understand how PAX3::FOXO1 is regulated and targeting the regulators of PAX3::FOXO1. By understanding and targeting the regulation of PAX3::FOXO1, we hope to bring new therapies for fusion positive rhabdomyosarcoma. Additionally, these regulatory mechanisms may also be active in other transcription driven cancers such as the EWSR1::FLI1 driven Ewings Sarcoma.
Our lab is also interested in exploring the epigenetic landscape of pediatric solid tumors and trying to understand how dysregulation in the epigenome drives oncogenesis. We utilize various CRISPR mediated genetic techniques to interrogate the regulators of epigenome focusing on the histone lysine demethylases (KDMs). KDMs are an understudied group of epigenetic regulators which can be targeted for therapeutic effect. We explore the role of KDMs in pediatric solid tumors and hope to identify potential targets for drug development. -
Norman J. Lacayo, MD
Associate Professor of Pediatrics (Hematology and Oncology)
Current Research and Scholarly InterestsPediatric Hematology/Oncology, Phase I drug studies for refractory and relapsed leukemia; genomic studies, biologic risk-stratification and treatment of acute myeloid leukemia; prediction or induction response and risk of relapse using phosphoproteomics in childhood AML; novel MRD techniques in childhood ALL.
